Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some of the main points from a debate held at COMy 2022 which focused on immunotherapies replacing autologous stem cell transplant (autoSCT) in myeloma. Dr Richardson first highlights the benefits of autoSCT, including improved progression-free survival (PFS) and overall survival (OS), and further explains the importance of melphalan in myeloma treatment. Following this, Dr Richardson comments on the future of myeloma therapy and whether treatment approaches can be improved with novel immunotherapies including CAR-T and antibodies, as well as the importance of using measurable residual disease (MRD) as a guide. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.